Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategy

Set Alert for Strategy

Shire Aims To Stay On Top In Hemophilia With Novimmune Pact

Having become embroiled in a legal tussle with Roche last week concerning the latter's emicizumab, Shire has licensed a hemophilia A bispecific monoclonal antibody of its own.

Blood & Coagulation Disorders Deals Research & Development
Advertisement

Strategy

Set Alert for Strategy

Latest From Strategy

Freshly Funded Symic Bio Plays In The Matrix

Emerging Company Profile: Symic Bio recently raised $30m in a Series B financing. CEO Ken Horne talks about the firm's therapeutic focus on the body's extracellular matrix as a therapeutic target, and its two lead programs in peripheral vein graft failure prevention and knee osteoarthritis.

StartUps and SMEs Companies

Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard

Howard Liang comes from an investment background with years of experience honed as the former managing director and head of biotech equity research at Leerink Partners. He became Beigene's CFO and Chief Strategy Officer in 2015 as the Chinese biotech prepared for its initial public offering on Nasdaq, and has since seen the Beijing-based firm leap onto the world stage with differentiated immuno-oncology and BTK inhibitor assets.

Commercial BioPharmaceutical

As Digital Channels Grow In Importance, AZ, Lilly, GSK Seen As Key Engagers

Digital physician engagement channels appear to be closing in on the traditional face-to-face approach, with China surging ahead on the digital path. The US and China appear more or less in sync when it comes to self-directed web-detailing, while AstraZeneca, Lilly and GSK lead the charts in terms of digital engagement as perceived by healthcare professionals, a new survey shows.

Commercial Strategy

Provenge To Drive Sanpower Growth And Wider China Cell Therapy Market?

China will provide a rising market potential for Sanpower’s newly acquired Dendreon and its Provenge product for prostate cancer, as part of the Chinese firm’s broader strategy, and the deal could also have an impact on the regulatory climate for cellular immunotherapies in China.

China Commercial

China’s HEC Plans Novel IPF Study To Make Splash In US

Tommy Lin, head of Business Development and Global Licensing for HEC Pharma, talks to Scrip’s Brian Yang on how the Chinese domestic drug company is looking to develop its anti-fibrosis drug in the US.

Commercial China

Interview: Setting The Course For Takeda’s R&D Future (Part 2)

Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company’s chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 12 months.

Commercial Strategy
See All
UsernamePublicRestriction

Register